Drug
Sarpogrelate clinical trials
Also written Anplag and MCI-9042.
- studies test it
- 19
- open now
- 0
- in phase 3
- 3
- first study started
- 2001
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
19 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2004 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 3
- 3
- Phase 4
- 6
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 8
Daewoong Pharmaceutical Co. LTD. (4) · Yuhan Corporation (2) · Seoul National University Bundang Hospital (2) · Mitsubishi Tanabe Pharma Corporation (2) · Alvogen Korea (2) · University of Karachi (1) · Ajou University School of Medicine (1) · Korea United Pharm. Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses sarpogrelate is read from its arms, and is right about nine times in ten.
Testing it · 19
- Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive DiseaseCompletedPhase 4Yuhan CorporationNCT06046196Written as Sarpogrelate SR
- Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting ConditionCompletedPhase 1University of KarachiNCT04941196Written as Anplag (Ticagrelor 90 mg)
- Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)CompletedPhase 4Yuhan CorporationNCT01869881Written as Anplag(Sarpogrelate)
- Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting ConditionsCompletedPhase 1Daewoong Pharmaceutical Co. LTD.NCT03947489Written as Sarpogrelate HCL 300mg
- Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed ConditionsStatus unknownPhase 1Daewoong Pharmaceutical Co. LTD.NCT03947528Written as Sarpogrelate HCL 300mg
- A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fasting ConditionsCompletedPhase 1Daewoong Pharmaceutical Co. LTD.NCT03573622Written as Anpl-one SR Tab. 300mg
- A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Feeding ConditionsCompletedPhase 1Daewoong Pharmaceutical Co. LTD.NCT03574285Written as Anpl-one SR Tab. 300mg
- The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary SpasmStatus unknownPhase 4Samsung Medical CenterNCT01674686Written as Sarpogrelate
- SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) StudyStatus unknownPhase 4Seoul National University HospitalNCT02959606Written as Sarpogrelate SR 300mg
- Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Coronary Artery DiseaseCompletedPhase 4Seoul National University Bundang HospitalNCT02607436Written as Sarpogrelate
- Effect of Sarpogrelate on Platelet Aggregation in Patients With Cerebral Infarction: Dose-responsive Clinical Pharmacology StudyCompletedPhase 3Mitsubishi Tanabe Pharma CorporationNCT00147303Written as MCI-9042
- Sarpogrelate Drug InteractionCompletedPhase 1Ajou University School of MedicineNCT02097511Written as Sarpogrelate
- Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' StudyCompletedPhase 3Seoul National University Bundang HospitalNCT02294643Written as Sarpogrelate
- Pharmacokinetics and Food Effect of Sarpogrelate HCl CR Formulation in Comparison to Immediate-release FormulationCompletedPhase 1Korea United Pharm. Inc.NCT01841086Written as Anplag
- Impact of Sarpogrelate in the Function of Endothelial Progenitor CellsStatus unknownNot applicableAichi Gakuin UniversityNCT01548274Written as Sarpogrelate
- Pharmacokinetic / Pharmacodynamic (PK/PD) Study of Multiple Doses of DP-R202 in Healthy VolunteersCompletedPhase 1Alvogen KoreaNCT01429688Written as Anplag
- Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male VolunteersCompletedPhase 1Alvogen KoreaNCT01421563Written as Anplag
- The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney DiseaseStatus unknownPhase 4Seoul National University Boramae HospitalNCT01165567Written as sarpogrelate
- Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS)CompletedPhase 3Mitsubishi Tanabe Pharma CorporationNCT00129805Written as MCI-9042
Codes
What other systems call sarpogrelate · ClinicalTrials.gg INT003515
- MeSH (NLM) C064294sarpogrelateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 19P708E787SARPOGRELATEConfirmed FDA, NLM, Wikidata
- Wikidata Q44931sarpogrelateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73158SarpogrelateOne source FDA
- DrugBank DB12163One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C064294 | sarpogrelate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 19P708E787 | SARPOGRELATE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q44931 | sarpogrelate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73158 | Sarpogrelate | One source FDA |
| DrugBank | DB12163 | — | One source Wikidata |
Also registered as sarpogrelate hydrochloride (UNII FQN8N8QP1B).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.